Skip to main navigation
Go to Upstream Bio homepage Upstream Bio, Targeting Inflammation at Its Source for Better Health
  • About
    • Leadership
    • Board
  • Science
    • TSLP
    • Publications
  • Pipeline
    • Verekitug
  • Patients
    • Clinical Trials
    • Disease Focus
  • Join Us
  • Investors
    • News Releases
    • Events & Presentations
      • Events
      • Presentations
    • Stock
      • Stock Quote & Chart
      • Analyst Coverage
    • Corporate Governance
      • Documents & Charters
      • Committee Composition
    • Financial Information
      • SEC Filings
    • Shareholder Services
      • Investor FAQs
      • Email Alerts
      • Contact Us
About
Science
Pipeline
Patients
Join Us
Investor
News
Back
Team
  • Leadership
  • Board
  • Advisors
  • Investors
Back
News
  • Press Releases
  • In The News
Back
Investor
  • Overview
  • News & Events
    • News Releases
    • Events
    • Presentations
  • Stock
    • Stock Quote & Chart
  • Corporate Governance
    • Documents & Charters
    • Committee Composition
  • Financial Information
    • SEC Filings
  • Shareholder Services
    • Investor FAQs
    • Email Alerts
    • Contact Us

SEC Filing Details

Document Details

Form
SCHEDULE 13G/A
Filing Date
Aug 12, 2026
Document Date
Aug 12, 2026
Form Description
SCHEDULE 13G/A - Description
Filing Group
Other
Company
Upstream Bio
Issuer
UPSTREAM BIO, INC.

Filing Formats

View HTML
Download PDF
Download DOC
Download XLS
Upstream Bio, Targeting Inflammation at Its Source for Better Health
  • LinkedIn
  • Twitter

info@upstreambio.com
890 Winter Street
Suite 200
Waltham, MA 02451

  • About
    • Board of Directors
    • Leadership
  • Science
    • TSLP
    • Publications
  • Pipeline
    • Verekitug
  • Patients
    • Clinical Trials
    • Disease Info
  • Join Us
  • Investors
© 2026 Upstream Bio | Privacy Policy | Terms of Use
EEA Investigators and Site Personnel Notice | Privacy Notice for Clinical Study Participants | Data Privacy Framework Privacy Notice